Cost-Effectiveness and Value of Information of Cabozantinib Treatment for Patients with Advanced Renal Cell Carcinoma After Failure of Prior Therapy in South Korea.

Siin KimSola HanHyungtae KimHae Sun Suh

Published in: Applied health economics and health policy (2021)

Cabozantinib was found to be cost-effective for advanced RCC patients after failure of prior therapy at a 2 GDP threshold. Future research that costs less than the estimated population EVPI would be worth considering for a comparison of cabozantinib and nivolumab.

Keyphrases

renal cell carcinoma
end stage renal disease
newly diagnosed
ejection fraction
metastatic renal cell carcinoma
chronic kidney disease
prognostic factors
healthcare
stem cells
patient reported outcomes
bone marrow
current status
replacement therapy
health information
social media